和鉑醫藥-B(02142.HK)香港公開發售獲78.54倍超額認購 發售價定為12.38港元/股
格隆匯 12 月 9日丨和鉑醫藥-B(02142.HK)發佈公告，公司全球發售約1.38億股股份，其中香港公開發售股份5529萬股，國際發售股份8293.1萬股，另有15%超額配股權；發售價已釐定為每股發售股份12.38港元，每手買賣單位1000股；摩根士丹利、BofA SECURITIES及中信證券為聯席保薦人，預期股份將於2020年12月10日於聯交所主板掛牌上市。
根據香港公開發售初步提呈發售的香港公開發售股份已獲超額認購。合共接獲115,188份有效申請，認購合共約10.86億股香港公開發售股份，相當於根據香港公開發售初步可供認購的香港公開發售股份總數約78.54倍。根據國際發售初步提呈發售的發售股份已獲超額認購，相當於根據國際發售初步可供認購的發售股份總數約八倍。
基於發售價每股12.38港元，根據相關基石投資協議，公司的基石投資者已認購合共5761.2萬股發售股份，合共相當於緊隨全球發售完成後公司已發行股本約7.50%；及全球發售項下的發售股份數目約41.68%，在兩種情況下均假設超額配股權未獲行使及並無根據股份計劃發行股份。
根據發售價每股12.38港元，公司將自全球發售收取的所得款項淨額估計約為15.988億港元(假設超額配股權未獲行使)。其中，所得款項淨額37%預期將用於撥資公司的核心產品，包括巴託利單抗(HBM9161)及特那西普(HBM9036)；約23%預期將用於撥資公司的支柱資產HBM4003在大中華區及澳洲的進行中及計劃進行的臨牀試驗、籌備在大中華區、美國及其他司法權區的註冊備案及潛在商業化推出；約15%預期將用於撥資公司其他正在尋求IND批准及尚未開始臨牀試驗或臨牀前研究的候選藥物(包括HBM9302、HBM1007、HBM7008及其他新候選藥物)的研發工作；約12%預期將用於撥資發現從和鉑抗體平台所產生的創新分子；約5%預期將用於撥資持續改進公司的平台技術，以及通過和鉑抗體平台物色授權合作機會；及約8%預期將用作營運資金及其他一般企業用途。倘超額配股權獲悉數行使，則公司將就因超額配股權獲行使而將予發行及配發的2073.3萬股額外發售股份收取額外所得款項淨額約2.464億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
